Somchai Pinlaor Selected Research

Dimethylnitrosamine (Nitrosodimethylamine)

8/2021	CagA+ Helicobacter pylori infection and N-nitrosodimethylamine administration induce cholangiocarcinoma development in hamsters.
2/2018	Melatonin suppresses eosinophils and Th17 cells in hamsters treated with a combination of human liver fluke infection and a chemical carcinogen.
3/2016	Upregulation of 14-3-3 eta in chronic liver fluke infection is a potential diagnostic marker of cholangiocarcinoma.
11/2015	MRI and (1)H MRS findings of hepatobilary changes and cholangiocarcinoma development in hamsters infected with Opisthorchis viverrini and treated with N-nitrosodimethylamine.
2/2014	Increase of exostosin 1 in plasma as a potential biomarker for opisthorchiasis-associated cholangiocarcinoma.
10/2013	Melatonin inhibits cholangiocarcinoma and reduces liver injury in Opisthorchis viverrini-infected and N-nitrosodimethylamine-treated hamsters.
4/2013	Annexin A1: A new immunohistological marker of cholangiocarcinoma.
1/2012	Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma.
7/2011	Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis.
6/2011	Involvement of c-Ski oncoprotein in carcinogenesis of cholangiocacinoma induced by Opisthorchis viverrini and N-nitrosodimethylamine.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Somchai Pinlaor Research Topics

Disease

42	Cholangiocarcinoma 01/2022 - 09/2003
32	Neoplasms (Cancer) 01/2022 - 08/2005
31	Infections 08/2021 - 09/2003
23	Opisthorchiasis 01/2022 - 07/2008
22	Inflammation (Inflammations) 08/2021 - 09/2003
16	Carcinogenesis 01/2017 - 09/2003
12	Fibrosis (Cirrhosis) 01/2021 - 06/2009
5	Neoplasm Metastasis (Metastasis) 09/2021 - 07/2011
5	Body Weight (Weight, Body) 01/2021 - 10/2010
5	Digestive System Diseases 01/2019 - 03/2012
2	Persistent Infection 01/2021 - 09/2003
2	Parasitic Diseases (Parasitic Disease) 01/2021 - 03/2008
2	Cholangitis 01/2017 - 01/2014
2	Hyperplasia 08/2012 - 09/2010
1	Diabetes Complications 01/2022
1	Dyslipidemias (Dyslipidemia) 01/2022
1	Fatty Liver 01/2022
1	Strongyloidiasis 10/2021
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Dysbiosis 01/2020

Drug/Important Bio-Agent (IBA)

17	Biomarkers (Surrogate Marker)IBA 11/2019 - 06/2004
16	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2005
12	8-Hydroxy-2'-DeoxyguanosineIBA 08/2021 - 09/2003
11	Dimethylnitrosamine (Nitrosodimethylamine)IBA 08/2021 - 10/2009
9	8-nitroguanineIBA 12/2013 - 09/2003
8	Praziquantel (Biltricide)FDA Link 01/2019 - 09/2006
7	Pharmaceutical PreparationsIBA 01/2022 - 03/2012
7	CurcuminIBA 01/2021 - 10/2009
6	CytokinesIBA 01/2022 - 06/2009
6	EnzymesIBA 01/2019 - 12/2010
5	Matrix Metalloproteinases (MMPs)IBA 08/2012 - 06/2009
4	Proliferating Cell Nuclear Antigen (PCNA)IBA 08/2021 - 06/2004
4	Immunoglobulin G (IgG)IBA 01/2019 - 03/2012
4	AntigensIBA 04/2018 - 03/2012
4	MelatoninIBA 02/2018 - 10/2010
4	Oxygen (Dioxygen)IBA 12/2014 - 09/2003
4	Messenger RNA (mRNA)IBA 12/2014 - 06/2009
4	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2013 - 08/2004
4	Hydroxyproline (4 Hydroxyproline)IBA 08/2012 - 06/2009
4	Cyclin D1IBA 04/2012 - 10/2009
3	FructoseIBA 01/2022 - 11/2019
3	CarcinogensIBA 08/2021 - 09/2006
3	LipidsIBA 11/2019 - 04/2013
3	Antiparasitic Agents (Antiparasitics)IBA 09/2019 - 03/2008
3	ImmunosorbentsIBA 01/2019 - 01/2017
3	NitrogenIBA 12/2014 - 09/2003
3	Superoxide DismutaseIBA 12/2013 - 05/2012
3	CollagenIBA 08/2012 - 06/2009
2	AlbuminsIBA 01/2022 - 12/2013
2	CreatinineIBA 01/2022 - 03/2008
2	Thymidylate SynthaseIBA 05/2021 - 12/2018
2	Fluorouracil (Carac)FDA LinkGeneric 05/2021 - 12/2018
2	CholesterolIBA 01/2021 - 04/2013
2	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 03/2012
2	Gemcitabine FDA Link 09/2019 - 05/2018
2	Anthocyanins (Anthocyanin)IBA 05/2018 - 12/2014
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2017 - 08/2009
2	Orosomucoid (Seromucoid)IBA 01/2017 - 01/2012
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 12/2014 - 04/2012
2	OxysterolsIBA 12/2014 - 03/2012
2	AntibodiesIBA 01/2014 - 03/2012
2	AntioxidantsIBA 10/2013 - 05/2012
2	Tissue Inhibitor of Metalloproteinase-2IBA 08/2012 - 06/2009
2	NF-kappa B (NF-kB)IBA 05/2012 - 09/2006
2	Immunoglobulin A (IgA)IBA 03/2012 - 03/2012
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2012 - 08/2004
2	Tyrosine (L-Tyrosine)FDA Link 01/2012 - 09/2005
2	Nucleic AcidsIBA 08/2004 - 09/2003
1	oxidized low density lipoproteinIBA 01/2022
1	Uric Acid (Urate)IBA 01/2022
1	Alanine Transaminase (SGPT)IBA 01/2022
1	hydroxide ionIBA 01/2022
1	LDL CholesterolIBA 01/2022
1	MucinsIBA 09/2021
1	HMGB1 Protein (HMG1)IBA 08/2021
1	Interleukin-8 (Interleukin 8)IBA 08/2021
1	Tricarboxylic AcidsIBA 01/2021
1	phenylacetylglycineIBA 01/2021
1	malic acid (malate)IBA 01/2021
1	Amino Acids FDA Link 01/2021
1	Ethyl MethanesulfonateIBA 01/2021
1	muricholic acidIBA 01/2021
1	FumaratesIBA 01/2021
1	GlobulinsIBA 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2021
1	GlycopeptidesIBA 01/2021
1	MutagensIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Glutamic Acid (Glutamate)FDA Link 01/2021
1	AgarIBA 04/2020
1	Sodium Glutamate (Accent)IBA 01/2020
1	Interleukin-33IBA 01/2020

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 10/2021 - 01/2018
3	Therapeutics 09/2011 - 10/2009
2	Chemoprevention 01/2018 - 05/2014
2	Oral Administration 12/2014 - 10/2010
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022
1	Aftercare (After-Treatment) 10/2021
1	Transplantation 09/2021